NPS Pharma's Gattex Picked by Providers to Support Distribution, Home-Based Clinical Care Services
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that it has established a patient-centric distribution and clinical service network for Gattex^® (Teduglutide [rDNA origin]) for Injection, for subcutaneous use. The network is comprised of leading specialty home infusion providers, including Accredo Health Group, Inc.; BioScrip; Inc.; Coram, LLC; ThriveRx; and Walgreens Infusion Services. In addition to dispensing Gattex, the company's contracted providers will provide clinical services to support the use of Gattex in reducing dependence on parenteral nutrition (PN) and intravenous fluids (IV) for patients with short bowel syndrome (SBS). Gattex was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2012 as a treatment for adults with SBS who are dependent on parenteral support. Gattex is the first-and-only FDA-approved therapy for the long-term treatment of SBS and the first major treatment advance for SBS in nearly 40 years.
By adding Gattex to their product offering the company's contracted home infusion providers will offer a wide range of personalized services to PN-dependent patients with short bowel syndrome through an interdisciplinary team of experienced infusion professionals, including nurses, pharmacists, dietitians, and support professionals.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.